...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Will NVAX spook the biotech market?
Also remember that after the 80%+ drop in price after market close, NVAX still has triple the market cap of RVX (dollar adjusted) and yet, on a quick look, probably not as much market potential as RVX (even if NVAX's trial was a success). Additionally given NAZDAQ vs TSX listing and dailey trade volumes (lowest Dailey volume for NVAX in the last 3 mos was 2.4 million shares) it is pretty safe to bet that relatively speaking almost no one even knows about RVX. I think if RVX takes a breather it won't be because of NVAX but who knows.
Share
New Message
Please login to post a reply